Accuracy Coverage Pricing Contact
AstraZeneca

AstraZeneca (AZN)

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium. Revenues over the next couple of years are forecast to fall. The dividend track record is excellent and an increased payout is forecast in spite of the falling revenues.

AstraZeneca dividends

AstraZeneca has a progressive dividend policy, intending to maintain or grow the dividend each year.

Payment of dividends

  1. First interim: announced end of July and paid in September
  2. Second interim: announced end of of January/beginning of February and paid in March

Fundamentals

Optimized Dividends

Annual Dividends

Year Amount Change
2006 89.6p
2007 93.0p 3.8%
2008 132.6p 42.6%
2009 141.4p 6.6%
2010 161.6p 14.3%
2011 175.5p 8.6%
2012 178.6p 1.8%
2013 175.76p (1.6%)
2014 178.22p 1.4%
2015 188.07p 5.5%
2016 218.9p 16.4%
2017 202.5p (7.5%)
2018 Login required
2019 Login required
2020 Login required

Dividends

Ex-Div Date Pay Date Year Type Frequency Status Amount
04 Aug 2010 13 Sep 2010 2010 Interim Semiannually Paid 44.9p
02 Feb 2011 14 Mar 2011 2010 Final Semiannually Paid 116.7p
03 Aug 2011 12 Sep 2011 2011 Interim Semiannually Paid 51.9p
15 Feb 2012 19 Mar 2012 2011 Final Semiannually Paid 123.6p
08 Aug 2012 10 Sep 2012 2012 Interim Semiannually Paid 58.1p (90c)
13 Feb 2013 18 Mar 2013 2012 Final Semiannually Paid 120.5p (190c)
14 Aug 2013 16 Sep 2013 2013 Interim Semiannually Paid 59.2p (90c)
19 Feb 2014 24 Mar 2014 2013 Final Semiannually Paid 116.56p (190c)
13 Aug 2014 15 Sep 2014 2014 Interim Semiannually Paid 53.22p (90c)
19 Feb 2015 23 Mar 2015 2014 Final Semiannually Paid 125p (190c)
13 Aug 2015 14 Sep 2015 2015 Interim Semiannually Paid 57.69p (90c)
18 Feb 2016 21 Mar 2016 2015 Final Semiannually Paid 130.38p (190c)
11 Aug 2016 12 Sep 2016 2016 Interim Semiannually Paid 68.7p (90c)
16 Feb 2017 20 Mar 2017 2016 Final Semiannually Paid 150.2p (190c)
10 Aug 2017 11 Sep 2017 2017 Interim Semiannually Paid 68.9p (90c)
15 Feb 2018 19 Mar 2018 2017 Final Semiannually Paid 133.6p (190c)
09 Aug 2018 10 Sep 2018 2018 Interim Semiannually Paid 69.618p (90c)
Login Login 2018 Final Semiannually Forecast Login
Login Login 2019 Interim Semiannually Forecast Login
Login Login 2019 Final Semiannually Forecast Login
Login Login 2020 Interim Semiannually Forecast Login
Login Login 2020 Final Semiannually Forecast Login
Login Login 2021 Interim Semiannually Forecast Login

Recent news articles

Investment Tools Limited

Financial Highlights

Read more
Investment Tools Limited

Core EPS in the year up by 7% and by 22% in Q4 2015

Read more
Investment Tools Limited

Total H1 Revenue up 1%; Core Gross margin over 83%, up 1% point

Read more
Investment Tools Limited

Financial results for 2014 in line with upgraded Company guidance given with third quarter 2014 results.

Read more
Investment Tools Limited

Revenue in the second quarter was $6,454 million, up 4%* - second consecutive quarter of revenue growth. Half year revenue up 3%, driven by the five growth platforms.

Read more
Investment Tools Limited

As expected, third quarter revenue declined due to the ongoing impact from products with recent losses of exclusivity.  The 4 percent decline in revenue on a constant currency basis, combined with continued investment in our growth platforms and scientific leadership resulted in a greater decline in Core earnings per share.  The late-stage pipeline continued to grow; since the half year update there have been three new Phase III programme starts and three regulatory filings were accepted for review.

Read more
Investment Tools Limited

Investors Chronicle – Dividend of the week – Number fifteen

Read more
Investment Tools Limited

Revenue in the second quarter declined by 4 percent at constant exchange rates (CER), as the impact from products with recent loss of exclusivity has moderated from the levels experienced in recent quarters. Revenue for the rest of the portfolio was up 4 percent, fuelled by a double-digit increase from the five growth platforms. The pipeline was further strengthened by the addition of three promising late-stage assets in core therapeutic areas of cardiovascular/metabolism and respiratory diseases. 

Read more
Investment Tools Limited

Financial performance for the full year reflects the loss of exclusivity on several brands. At constant exchange rates (CER), revenue declined by 15 percent and Core EPS declined by 9 percent.

Read more
Investment Tools Limited

Ok. It is big Pharma time. I am going to use the DividendMax tool to select on sector and then use other criteria to try and whittle down to the best Pharma dividend stock out there and that will become my dividend of the week.

Read more

AstraZeneca optimized dividend - 12 month history

Optimized dividend graph demo

AstraZeneca share price - 12 month history

You're currently viewing outdated and/or artificial data.

Try the real thing now:

Activate Free Trial